2340-9894

2340-9894

S2340-98942021000300328

10.30827/ars.v62i3.16882

España

00 09 2021

00 09 2021

62 3 328 342

1

2014 10 2 2

2

2015 38 3 3

245-52

3

2015 28 1 1

4

2019 36 Suppl 1 Suppl 1

65-99

5

2010 18 3 3

289-96

6

2020 79 6 6

819-28

7

Sociedad Española de Reumatología 2016

8

2016 33 2 2

75-85

9

2019 49 3 3

337-50

10

11

2006 25 17 17

1899-906

12

European Medicines Agency 2014

13

2017 19 1 1

169

14

2001 357 9252 9252

251-6

15

1994 37 4 4

529-36

16

AEMPS 2020

17

18

2020 25 131 131

19

2018 41 2 2

163-71

20

2013 35 4 4

431-9

21

2014 78 3 3

184-7

22

2006 9 1 1

64-9

23

Thai Study Group 2007 15 6 6

605-14

24

2012 15 1 1

69-77

25

2001 44 11 11

2539-47

26

2002 12 31 31

7-9

27

European Medicines Agency

28

2004 63 12 12

1611-7

29

2016 75 1 1

37-44

30

2018 38 8 8

1413-28

31

2018 6 13 13

170

32

2010 16 341 341

33

2016 03 18 18

256

34

2017 56 6 6

989-98

35

CONCEPT Investigation Group 2018 77 2 2

36

European Medicines Agency 2020

37

2002 162 18 18

2113-23

38

2017 148 12 12

539-47

39

2015 20 3 3

4277-89

40

2018 2nd

41

2016 45 4 Suppl 4 Suppl

S12-7

42

2017 76 9 9

1537-43

43

Agencia Española de Medicamento y Productos Sanitarios 2013

44

Grupo del estudio VECTRA 2010 6 4 4

187-95

45

2006 61 4 4

341-6